PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31958741-3 2020 In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation. Lidocaine 34-43 interleukin 6 Mus musculus 161-174 31958741-3 2020 In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation. Lidocaine 34-43 interleukin 6 Mus musculus 176-180 31958741-3 2020 In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation. Lidocaine 206-215 interleukin 6 Mus musculus 176-180 31958741-4 2020 Moreover, we have demonstrated that lidocaine reduces the release of TNF-alpha and IL-6 through the reduction of the expression of GLUT1 and HK2 to further suppress HIF1alpha-induced aggravation of inflammatory cascades. Lidocaine 36-45 interleukin 6 Mus musculus 83-87 31209627-7 2019 CCI induced an significant increase of IBA1+ microglia accompanied by the increase of inflammatory cytokines IL-6 and IL-1beta, which were suppressed after lidocaine administration. Lidocaine 156-165 interleukin 6 Mus musculus 109-113